HeartBeam, Inc. and HeartNexus, Inc. have entered into a partnership that will combine HeartBeam’s credit‑card‑sized, cable‑free 3‑D vector electrocardiography (VECG) device with HeartNexus’s network of board‑certified cardiologists to provide a 24/7 cardiology reader service for patients experiencing cardiac symptoms outside traditional medical settings.
The service will deliver real‑time interpretation of the VECG data, peer‑to‑peer consultations, and on‑demand telemedicine visits, allowing patients to receive the value of a full 12‑lead ECG interpretation directly in their pocket. The reader service is scheduled to launch after the anticipated FDA clearance of HeartBeam’s 12‑lead ECG synthesis software, expected in the fourth quarter of 2025.
HeartBeam’s CEO, Robert Eno, said the partnership accelerates the company’s mission to make medical‑grade cardiac monitoring accessible beyond the walls of a medical facility. He added that integrating HeartNexus’s expertise will create a more connected, responsive, and patient‑centered model of cardiac care, potentially speeding adoption and revenue growth.
HeartBeam’s core technology captures 3‑D ECG signals and synthesizes them into a standard 12‑lead ECG, a capability that received FDA clearance for arrhythmia assessment in December 2024. The new partnership leverages this technology to expand HeartBeam’s reach beyond concierge and preventive cardiology practices into broader consumer and provider markets.
HeartNexus, which comprises a network of board‑certified cardiologists, has previously partnered with other telemedicine platforms to enhance cardiac care accessibility and diagnostic accuracy. The collaboration will also support HeartBeam’s early access program, which began in 2025 to refine clinical workflows and build an early adopter network.
Future plans for the ecosystem include AI‑driven wellness features, community engagement tools, and wearable integration, positioning HeartBeam to offer a comprehensive cardiac monitoring and care platform.
The partnership underscores both companies’ commitment to improving cardiac care delivery through technology and expert interpretation, with the FDA clearance of the 12‑lead ECG synthesis software serving as a key milestone in the commercialization roadmap.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.